KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Liabilities and Shareholders Equity (2019 - 2025)

Royalty Pharma's Liabilities and Shareholders Equity history spans 7 years, with the latest figure at $19.6 billion for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 7.67% year-over-year to $19.6 billion; the TTM value through Dec 2025 reached $74.9 billion, up 6.92%, while the annual FY2025 figure was $19.6 billion, 7.67% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $19.6 billion at Royalty Pharma, up from $19.3 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $19.6 billion in Q4 2025 and bottomed at $15.9 billion in Q3 2023.
  • The 5-year median for Liabilities and Shareholders Equity is $17.6 billion (2021), against an average of $17.4 billion.
  • The largest annual shift saw Liabilities and Shareholders Equity fell 10.28% in 2023 before it grew 13.79% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $17.5 billion in 2021, then fell by 4.01% to $16.8 billion in 2022, then dropped by 2.57% to $16.4 billion in 2023, then grew by 11.24% to $18.2 billion in 2024, then grew by 7.67% to $19.6 billion in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Liabilities and Shareholders Equity are $19.6 billion (Q4 2025), $19.3 billion (Q3 2025), and $18.3 billion (Q2 2025).